GALT
GALECTIN THERAPEUTICS INCCompany Information
- Company Name
- GALECTIN THERAPEUTICS INC
- CIK
- CIK0001133416
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- GALT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GALT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-02-06
- Last sale
- 2026-07-14
- Shares purchased (TTM)
- 12,500
- Shares sold (TTM)
- 759,383
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 15,438,909
- Shares outstanding
- 65,875,000
- Ownership
- 23.44%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 34.01%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 13 | 14 | 18 | 12 | 14 | 7 | 15 | 27 | 26 | 24 | 26 | 20 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
| Assets Current | 15 | 16 | 19 | 13 | 15 | 9 | 17 | 29 | 27 | 25 | 28 | 22 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Property Plant And Equipment Net | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Assets | 15 | 16 | 20 | 13 | 16 | 10 | 17 | 29 | 28 | 26 | 28 | 22 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 3 | 5 | 6 | 7 | 6 | 3 | 4 | 4 | 6 | 3 | ||||||
| Accrued Liabilities Current | 4 | 4 | 5 | 5 | 5 | 7 | 8 | 12 | 11 | 9 | 9 | 8 | ||||||
| Derivative Liabilities Current | 6 | - | 0 | 4 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
| Dividends Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 152 | 7 | 8 | 136 | 11 | 111 | 35 | 25 | 15 | 13 | 16 | 11 | ||||||
| Derivative Liabilities Noncurrent | 0 | 3 | 4 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | 0 | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 152 | 146 | 146 | 136 | 133 | 122 | 121 | 121 | 110 | 97 | 88 | 73 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 308 | 305 | 304 | 301 | 299 | 297 | 296 | 295 | 294 | 292 | 292 | 291 | ||||||
| Retained Earnings Accumulated Deficit | -447 | -438 | -433 | -427 | -419 | -411 | -402 | -390 | -378 | -366 | -354 | -344 | ||||||
| Stockholders Equity | -139 | -132 | -128 | -125 | -119 | -114 | -105 | -94 | -84 | -73 | -62 | -53 | ||||||
| Liabilities And Stockholders Equity | 15 | 16 | 20 | 13 | 16 | 10 | 17 | 29 | 28 | 26 | 28 | 22 | ||||||
| Temporary Equity Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Aggregate Amount Of Redemption Requirement | 7,966 | 7,966 | 7,966 | 8,018 | 8,018 | 7,939 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
| Temporary Equity Liquidation Preference | 1,760 | 1,760 | 1,760 | 1,760 | 1,760 | 1,760 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Outstanding | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Liquidation Preference Value | 1,185 | 1,210 | 1,210 | 1,210 | 1,210 | 1,235 | 1,235 | 1 | 1 | 1 | 1,235 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 66 | 66 | 65 | 64 | 64 | 63 | 63 | 62 | 62 | 62 | 62 | 62 | ||||||
| Shares Outstanding | 66 | 66 | 65 | 64 | 64 | 63 | 63 | 62 | 62 | 62 | 62 | 62 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGALECTIN THERAPEUTICS INC (GALT) — SEC Financial Statements & Analysis
GALECTIN THERAPEUTICS INC (GALT) is a pharmaceutical preparations company, incorporated in NV. GALECTIN THERAPEUTICS INC trades on Nasdaq as: GALT. GALECTIN THERAPEUTICS INC (GALT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, GALECTIN THERAPEUTICS INC carries a market cap of $305.66M, a P/E ratio of -10.91x, a P/B ratio of -2.21x, an enterprise value of $292.39M, and an EV/EBITDA multiple of -18.72x. On profitability, it posts a Return on Equity (ROE) of 21.76% and a Return on Assets (ROA) of -184.09%. Per share, it reports EPS of $-0.43, diluted EPS of $-0.43, free cash flow per share of $-0.24, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -30.40% year-over-year and EPS growth of -32.97% year-over-year. On the balance sheet, it maintains a current ratio of 0.10x, a quick ratio of 0.09x, working capital of $-136.96M, a debt-to-equity ratio of -1.09x, a debt ratio of 10.23, an interest coverage ratio of -2.02x, free cash flow of $-15.89M (TTM), and net debt of $-13.27M. Figures sourced from SEC EDGAR.
- Market Cap
- $305.66M
- P/E TTM
- -10.91x
- EPS TTM
- $-0.43
- P/B TTM
- -2.21x
- ROE TTM
- 21.76%
- ROA TTM
- -184.09%
- Debt To Equity
- -1.09x
- Free Cash Flow TTM
- $-15.89M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is GALECTIN THERAPEUTICS INC in?
GALECTIN THERAPEUTICS INC (GALT) operates in the Pharmaceutical Preparations industry.
What exchange does GALT trade on?
GALECTIN THERAPEUTICS INC (GALT) trades on the Nasdaq.
Where is GALECTIN THERAPEUTICS INC incorporated?
GALECTIN THERAPEUTICS INC is incorporated in NV.
When was GALECTIN THERAPEUTICS INC (GALT)'s most recent SEC filing?
GALECTIN THERAPEUTICS INC (GALT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is GALT's market cap?
GALECTIN THERAPEUTICS INC (GALT) has a market capitalization of $305.66M as of 2026-06-30.
What is GALT's EPS (earnings per share)?
GALECTIN THERAPEUTICS INC (GALT)'s trailing twelve month EPS is $-0.43 as of 2026-06-30.
What is GALT's ROE (return on equity)?
GALECTIN THERAPEUTICS INC (GALT)'s trailing twelve month Return on Equity (ROE) is 21.76% as of 2026-06-30.
What is GALT's ROA (return on assets)?
GALECTIN THERAPEUTICS INC (GALT)'s trailing twelve month Return on Assets (ROA) is -184.09% as of 2026-06-30.
What is GALT's EV/EBITDA?
GALECTIN THERAPEUTICS INC (GALT)'s trailing twelve month EV/EBITDA is -18.72x as of 2026-06-30.